AI Article Synopsis
- The activated protein C resistance (APCr) phenotype is common in about 40% of thrombophilic Mexican Mestizo individuals, but most don't have the factor V Leiden mutation.
- Researchers investigated other factor V gene mutations like HR2, Cambridge, Hong Kong, and Liverpool.
- The study found FV Leiden in 10% and HR2 in 28% of individuals, concluding that these mutations are not significant contributors to thrombophilia in this population, suggesting further investigation is needed.
Article Abstract
The activated protein C resistance (APCr) phenotype is found in around 40% of thrombophilic Mexican Mestizo individuals; since only very few display the factor V gene Leiden (Arg506Gln) mutation, it was considered of interest looking for other factor V gene mutations associated to thrombophilia: The HR2 haplotype, the factor V Cambridge (Arg306Thr), the factor V Hong Kong (Arg306Gly) and the FV Liverpool (Ile359Thr). In 39 individuals, the FV Leiden was found in 10%, the HR2 haplotype in 28%, the FV Hong Kong in 2%, whereas the FV Cambridge and FV Liverpool gene mutations were not found in any individual. In the subset of 10 patients with the APCr phenotype, the FV Leiden mutation was found only in 4 (40%) whereas the HR2 haplotype in 3 (30%); all the patients with the factor V Leiden mutation and 27% of those with the HR2 phenotype displayed the APCr phenotype. It is concluded that these polymorphisms of the factor V gene are not major contributors to the thrombophilia observed in Mexican Mestizos and that additional mutations in the FV gene should be looked for in those who display the APCr phenotype.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
-Segregation of c.1171C>T Stop Codon (p.R391*) in Gene and c.1691G>A Transition (p.R506Q) in Gene and Selected GWAS Multilocus Approach in Inherited Thrombophilia.
Genes (Basel)
June 2021
University Center for Studies on Gender Medicine, University of Ferrara, 44121 Ferrara, Italy.
Inherited thrombophilia (e.g., venous thromboembolism, VTE) is due to rare loss-of-function mutations in anticoagulant factors genes (i.
View Article and Find Full Text PDFMultiple Heritable and Acquired Risk Factors in a Case of Recurrent Retinal Vein Occlusion.
J Assoc Physicians India
March 2018
Department of Thrombosis and Haemostasis, National Institute of Immunohaematology, Mumbai, Maharashtra.
A 40 year old female presented with branch retinal vein occlusion in the right eye followed by a second episode, a year later, of central retinal vein occlusion in the left eye. The patient was found to be heterozygous for factor V Leiden and factor V HR2 haplotype G5380A. She had a history of use of oral contraceptives, had reduced levels of tissue plasminogen activator, positive for lupus anticoagulant and diagnosed with hypertension post second episode of RVO.
View Article and Find Full Text PDFA Prothrombotic Score Based on Genetic Polymorphisms of the Hemostatic System Differs in Patients with Ischemic Stroke, Myocardial Infarction, or Peripheral Arterial Occlusive Disease.
Front Cardiovasc Med
June 2017
Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Background: While twin studies indicate a genetic component in arterial thrombosis such as ischemic stroke, myocardial infarction (MI), or peripheral arterial occlusive disease (PAOD), the clinical relevance of hemostatic polymorphisms in arterial thrombosis is a matter of debate.
Methods: We analyzed the prevalence of 13 hemostatic polymorphisms [ (including factor V and HR2 haplotype), , and ] in patients referred to a tertiary referral center. A "prothrombotic score" was calculated by dividing the number of risk-increasing polymorphisms for thrombosis minus the number of risk-lowering polymorphisms ( and ) by the number of polymorphisms tested.
Prothrombin polymorphism A19911G, factor V HR2 haplotype A4070G, and plasminogen activator-inhibitor-1 polymorphism 4G/5G and the risk of retinal vein occlusion.
Ophthalmic Genet
December 2017
c Department of Ophthalmology , Ludwigshafen Hospital, Ludwigshafen , Germany.
Background: Thus far, no data has become available to evaluate systematically the prevalences of prothrombin polymorphism A19911G (PT A19911G), factor V HR2 haplotype A4070G (FV A4070G), or plasminogen activator-inhibitor-1 polymorphism 4G/5G (PAI-1 4G/5G) in patients who develop retinal vein occlusion (RVO) without cardiovascular risk factors.
Materials And Methods: We retrospectively evaluated comprehensive thrombophilia data from 42 preselected RVO patients without cardiovascular risk factors. The prevalences of different gene mutations and polymorphisms including factor V Leiden mutation G1691A (FVL), FV A4070G, prothrombin mutation G20210A, PT A19911G, and PAI-1 4G/5G were compared with 241 healthy controls matched for age and sex.
Association Between Thrombophilic Gene Mutations and the Risk of Vascular Access Thrombosis in Hemodialysis Patients.
Ther Apher Dial
April 2016
Laboratory of Molecular Biology, Department of Hematology.
The cause of thrombosis in hemodialysis vascular access is considered to be of a multifactorial nature, including stenosis of the venous or arterial connection. Therefore, identification of relevant thrombotic risk factors could lead to an improved antithrombotic therapy. This case control study was performed to evaluate the relationship between Factor V (G1691A and A4070G) and Factor II polymorphisms and vascular access thrombosis in hemodialysis patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!